

Kosh Agarwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4671890/publications.pdf>

Version: 2024-02-01

284
papers

24,943
citations

23567

58
h-index

7160

153
g-index

294
all docs

294
docs citations

294
times ranked

17416
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e784-e793.	4.4	49
2	Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom-Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa. <i>Journal of Infectious Diseases</i> , 2022, 226, 995-1004.	4.0	8
3	The EASL-Lancet Liver Commission; protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet</i> , The, 2022, 399, 61-116.	13.7	257
4	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. <i>Journal of Hepatology</i> , 2022, 76, 1042-1050.	3.7	54
5	Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 921-943.	3.7	14
6	Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study. <i>Liver International</i> , 2022, 42, 1278-1286.	3.9	3
7	A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV “cure”™. <i>Journal of Hepatology</i> , 2022, 77, 245-248.	3.7	29
8	Michael Charles Kew - Frontrunner in Hepatology. <i>Journal of Hepatology</i> , 2022, 76, 754.	3.7	0
9	Global elimination of hepatitis C: a warning from the data. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 380-381.	8.1	2
10	Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2022, 77, 642-652.	3.7	17
11	Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2022, 77, 1265-1275.	3.7	21
12	A Very Short Course of HBIg+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2021, 53, 207-214.	0.6	3
13	Risk stratification in chronic hepatitis B patients for hepatocellular carcinoma surveillance: management in migrant sub-Saharan African populations. <i>Gut</i> , 2021, 70, 629-630.	12.1	2
14	Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of patients with COVID-19. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 320, C57-C65.	4.6	146
15	Circulating Pregenomic Hepatitis B Virus RNA Is Primarily Full-length in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogue Therapy. <i>Clinical Infectious Diseases</i> , 2021, 72, 2029-2031.	5.8	14
16	Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2021, 28, 168-176.	2.0	7
17	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	2.0	28
18	Severe alcohol-related liver disease admissions post-COVID-19 lockdown: canary in the coal mine?. <i>Frontline Gastroenterology</i> , 2021, 12, 354-355.	1.8	16

#	ARTICLE	IF	CITATIONS
19	Reply. Hepatology, 2021, 73, 870-871.	7.3	0
20	Current Management of Patients with HCV Genotype 5 or 6. , 2021, , 129-140.		0
21	Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). Mitochondrion, 2021, 57, 119-130.	3.4	40
22	Patterns and prediction of liver injury with persistent cholestasis in survivors of severe SARS-CoV-2 infection. Journal of Infection, 2021, 82, e11-e13.	3.3	10
23	Hepatitis B cure: How and when. Liver International, 2021, 41, 24-29.	3.9	4
24	Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses, 2021, 13, 1333.	3.3	2
25	A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure. Journal of Hepatology, 2021, 75, 424-434.	3.7	23
26	P084â€¦A MELD score â‰¥ 19 prior to anti-thymocyte globulin therapy for steroid resistant T cell-mediated rejection predicts poor 5-year transplant free survival. , 2021, , .		0
27	IDDF2021-ABS-0078â€¦Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD). , 2021, , .		0
28	Unmet Needs in Clinical Research Hepatitis B. , 2021, , 51-71.		0
29	Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 152-166.	8.1	85
30	Pregenomic HBV RNA and Hepatitis B Coreâ€Related Antigen Predict Outcomes in Hepatitis B e Antigenâ€Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy. Hepatology, 2020, 72, 42-57.	7.3	103
31	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis Bâ€Report From the 2019 EASLâ€AASLD HBV Treatment Endpoints Conference. Hepatology, 2020, 71, 1070-1092.	7.3	52
32	Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. Hepatology Communications, 2020, 4, 8-20.	4.3	43
33	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. Journal of Hepatology, 2020, 72, 431-440.	3.7	30
34	Reply to: â€œels resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for actionâ€; Journal of Hepatology, 2020, 72, 585-586.	3.7	3
35	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conferenceâ€; Journal of Hepatology, 2020, 72, 539-557.	3.7	208
36	Hepatitis B in subâ€Saharan Africaâ€How many patients need therapy?. Journal of Viral Hepatitis, 2020, 27, 560-567.	2.0	9

#	ARTICLE	IF	CITATIONS
37	EASL Recognition Award Recipient 2020: Prof. Patrick Marcellin. <i>Journal of Hepatology</i> , 2020, 73, 482-483.	3.7	0
38	The Role of RNA Interference in Functional Cure Strategies for Chronic Hepatitis B. <i>Current Hepatology Reports</i> , 2020, 19, 362-369.	0.9	6
39	EASL recommendations on treatment of hepatitis C: Final update of the series†. <i>Journal of Hepatology</i> , 2020, 73, 1170-1218.	3.7	671
40	Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	13.6	239
41	Sequential Cohort Analysis After Liver Transplantation Shows de Novo Extended Release Tacrolimus Is Safe, Efficacious, and Minimizes Renal Dysfunction. <i>Transplantation Direct</i> , 2020, 6, e528.	1.6	2
42	Successful liver transplantation for drug-induced vanishing bile duct syndrome. <i>BMJ Case Reports</i> , 2020, 13, e233052.	0.5	6
43	Will we need novel combinations to cure HBV infection?. <i>Liver International</i> , 2020, 40, 35-42.	3.9	12
44	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 441-453.	8.1	85
45	Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1. <i>Journal of Hepatology</i> , 2020, 72, 1097-1104.	3.7	37
46	Serum MicroRNA Signatures in Recovery From Acute and Chronic Liver Injury and Selection for Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 811-822.	2.4	17
47	Differential effect of interferon-alpha treatment on AEA and 2-AG levels. <i>Brain, Behavior, and Immunity</i> , 2020, 90, 248-258.	4.1	7
48	English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 168-181.	3.7	8
49	<sc>Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1439-1440.	3.7	2
50	IDDF2020-ABS-0060â€¦Impact of prior tenofovir disoproxil fumarate (TDF) treatment duration on tenofovir alafenamide (TAF) safety profile in virally suppressed chronic HBV patients switched from TDF to TAF. , 2020, , .		0
51	IDDF2020-ABS-0061â€¦Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB). , 2020, , .		0
52	Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C. <i>Journal of Hepatology</i> , 2019, 71, 1099-1105.	3.7	52
53	SAT-018-Relation of CT determined sarcopenia and anthropometry to serum C-reactive protein levels in patients with chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e633.	3.7	1
54	Antiviral treatment for hepatitis C: rebalancing cost, affordability, and availability. <i>The Lancet Global Health</i> , 2019, 7, e1150-e1151.	6.3	4

#	ARTICLE	IF	CITATIONS
55	Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. <i>Scientific Reports</i> , 2019, 9, 10529.	3.3	12
56	Hepatitis B virus infection in children and adolescents. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 466-476.	8.1	116
57	Hepatitis C virus infection in children and adolescents. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 477-487.	8.1	117
58	Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. <i>Journal of Infection</i> , 2019, 79, 503-512.	3.3	23
59	PS-181-Unacceptably low SVR rates in African patients with unusual HCV sub-genotypes : Implications for global elimination. <i>Journal of Hepatology</i> , 2019, 70, e111-e112.	3.7	3
60	FRI-213-HBV RNA at 6 months predicts HBeAg loss in nucleos (t)ide analogue treated HBeAg positive patients: Demonstration of clinical utility?. <i>Journal of Hepatology</i> , 2019, 70, e487.	3.7	0
61	FRI-387-Risk factors associated with early post-operative acute kidney injury requiring renal replacement therapy following liver transplantation. <i>Journal of Hepatology</i> , 2019, 70, e565.	3.7	0
62	PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. <i>Journal of Hepatology</i> , 2019, 70, e110.	3.7	2
63	FRI-159-Can HBcrAg and pre-genomic HBV RNA predict the risk of ALT flares after nucleoside analogue therapy withdrawal: delineating the clinical utility of new biomarkers?. <i>Journal of Hepatology</i> , 2019, 70, e458.	3.7	4
64	Strain elastography for noninvasive assessment of liver fibrosis: A prospective study with histological comparison. <i>Ultrasound</i> , 2019, 27, 262-271.	0.7	4
65	PS-055-The markers of HBV transcriptional activity-HBcrAg and pre-genomic HBV DNA during antiviral therapy with nucleos (t)ide analogue help to predict optimal timing of therapy withdrawal. <i>Journal of Hepatology</i> , 2019, 70, e33-e34.	3.7	3
66	FRI-397-Sepsis is a major risk factor for delirium post liver transplantation. <i>Journal of Hepatology</i> , 2019, 70, e569.	3.7	0
67	THU-233-Whole exome sequencing analysis of the role of rare human variation in chronic hepatitis B infection. <i>Journal of Hepatology</i> , 2019, 70, e267-e268.	3.7	0
68	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GSâ€9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2019, 70, 788-801.	7.3	180
69	THU-206-HBV DNA relapse after stopping nucleoside analogue therapy in patients with HBsAg loss: Detectable pre-genomic HBV RNA is a better predictor of relapse than ultra-sensitive HBsAg-â€implications for HBV cureâ€™. <i>Journal of Hepatology</i> , 2019, 70, e254.	3.7	1
70	Patientâ€reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. <i>Liver International</i> , 2019, 39, 1837-1844.	3.9	18
71	The association between hepatocellular carcinoma and directâ€acting antiâ€viral treatment in patients with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 204-214.	3.7	20
72	Sofosbuvir/velpatasvir for 12â€weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. <i>Journal of Hepatology</i> , 2019, 71, 660-665.	3.7	93

#	ARTICLE	IF	CITATIONS
73	FRI-183-A phase 3 study comparing switching from tenofovir disoproxil fumarate to tenofovir alafenamide with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results. <i>Journal of Hepatology</i> , 2019, 70, e470-e471.	3.7	0
74	LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naïve and treatment-suppressed chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, e130.	3.7	23
75	Reactivation of hepatitis B virus infection in patients with hematologic disorders. <i>Haematologica</i> , 2019, 104, 435-443.	3.5	40
76	IDDF2019-ABS-0134â€¦Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies. , 2019, , .		0
77	IDDF2019-ABS-0169â€¦A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results. , 2019, , .		0
78	Advancing Age and Comorbidity in a US Insured Populationâ€œBased Cohort of Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2019, 69, 959-973.	7.3	60
79	Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome. <i>Psychoneuroendocrinology</i> , 2019, 100, 276-285.	2.7	62
80	Glecaprevir/Pibrentasvir in patients with chronic <sc>HCV</sc> genotype 3 infection: An integrated phase 2/3 analysis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 337-349.	2.0	32
81	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. <i>Kidney International Reports</i> , 2019, 4, 257-266.	0.8	15
82	Hepatitis B Surface Antigen Loss: Too Little, Too Late and the Challenge for the Future. <i>Gastroenterology</i> , 2019, 156, 548-551.	1.3	15
83	Liver transplant listing for hepatitis Câ€œassociated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of directâ€œacting antiviral therapy. <i>Journal of Viral Hepatitis</i> , 2019, 26, 231-235.	2.0	20
84	Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 32-44.	8.1	22
85	Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2019, 70, 24-32.	3.7	35
86	Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. <i>ELife</i> , 2019, 8, .	6.0	28
87	A Shift in Thinking to Reduce Mother-to-Infant Transmission of Hepatitis B. <i>New England Journal of Medicine</i> , 2018, 378, 952-953.	27.0	13
88	Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. <i>Hepatology</i> , 2018, 67, 2113-2126.	7.3	22
89	Reducing the Number of Measurements in Liver Point Shear-Wave Elastography: Factors that Influence the Number and Reliability of Measurements in Assessment of Liver Fibrosis in Clinical Practice. <i>Radiology</i> , 2018, 287, 844-852.	7.3	35
90	Serum <sc>NGAL</sc> can act as an early renal safety biomarker during longâ€œterm nucleos(t)ide analogue antiviral therapy in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1139-1150.	2.0	2

#	ARTICLE	IF	CITATIONS
91	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , 2018, 68, 1298-1307.	7.3	158
92	Current and future directions of management of hepatitis B: steps toward a cure. <i>Future Virology</i> , 2018, 13, 189-209.	1.8	1
93	EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , 2018, 69, 461-511.	3.7	1,489
94	96-weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , 2018, 68, 672-681.	3.7	291
95	Reply to: "Reply to: Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries" <i>Journal of Hepatology</i> , 2018, 68, 864-866.	3.7	2
96	Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review. <i>Digestive and Liver Disease</i> , 2018, 50, 113-123.	0.9	5
97	Palliative care in end-stage liver disease: Time to do better?. <i>Liver Transplantation</i> , 2018, 24, 961-968.	2.4	39
98	Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. <i>Digestive and Liver Disease</i> , 2018, 50, 944-953.	0.9	33
99	Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1641-1649.e6.	4.4	29
100	Delineating the global challenges of hepatitis B virus infection. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 372-373.	8.1	6
101	Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 224-225.	8.1	1
102	HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues. <i>Journal of Viral Hepatitis</i> , 2018, 25, 886-893.	2.0	40
103	A183 SOFOSBUVIR-BASED ALL-ORAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 3 INFECTION: INTEGRATED ANALYSIS OF FIVE CLINICAL STUDIES. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 318-319.	0.3	0
104	Depression and anxiety in patients receiving interferon-alpha: The role of illness perceptions. <i>Journal of Health Psychology</i> , 2018, 23, 1405-1414.	2.3	13
105	Management of chronic hepatitis B before and after liver transplantation. <i>Frontline Gastroenterology</i> , 2018, 9, 79-84.	1.8	7
106	Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?. <i>Journal of Viral Hepatitis</i> , 2018, 25, 80-87.	2.0	6
107	Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 417-426.	4.4	191
108	Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature. <i>International Journal of STD and AIDS</i> , 2018, 29, 414-417.	1.1	19

#	ARTICLE	IF	CITATIONS
109	Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything. <i>Journal of Hepatology</i> , 2018, 68, 217-218.	3.7	8
110	Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ) in HCV genotype 2 or 3 infection. <i>Journal of Hepatology</i> , 2018, 68, 1069-1077.	3.7	10
111	Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. <i>Hepatology</i> , 2018, 67, 514-523.	7.3	124
112	Eliminating hepatitis C within low-income countries – The need to cure genotypes 4, 5, 6. <i>Journal of Hepatology</i> , 2018, 68, 814-826.	3.7	35
113	IDDF2018-ABS-0109 – SOFOSBUVIR/VELPATASVIR for 12 weeks in genotype 4 hcv-infected liver transplant recipients. , 2018, , .		0
114	A180 IMPROVED RENAL LABORATORY PARAMETERS IN CHB PATIENTS TREATED WITH TAF COMPARED WITH TDF. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 313-314.	0.3	0
115	The Role of Anti-HBs in Hepatitis B Reactivation during Direct-Acting Antiviral Therapy for Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2018, 23, 539-542.	1.0	4
116	Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1339-1345.	2.6	10
117	Long-term follow up of patients with chronic HCV and F2 or F3 fibrosis after achieving SVR with DAA-based therapy: results from the Gilead SVR registry. <i>Journal of Hepatology</i> , 2018, 68, S527-S528.	3.7	0
118	Whole genome viral sequencing reveals subgenotype specific dynamics of antiviral treatment response in HBeAg positive and treatment naive chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2018, 68, S778-S779.	3.7	0
119	The road map toward an hepatitis C virus-free transplant population. <i>American Journal of Transplantation</i> , 2018, 18, 2409-2416.	4.7	5
120	Achieving Cure From Hepatitis C Virus Is Good for More Than Just the Liver Graft. <i>Liver Transplantation</i> , 2018, 24, 997-998.	2.4	0
121	Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481878610.	3.2	19
122	HepFree: Screening migrant patients for viral hepatitis in primary care. A 90,000 patient randomised controlled trial indicates benefits are most obvious in older patients. <i>Journal of Hepatology</i> , 2018, 68, S51-S52.	3.7	1
123	Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens. <i>Journal of Hepatology</i> , 2018, 68, S67-S68.	3.7	12
124	HepCARE: A tool enabling the identification, assessment and management of viral hepatitis. An integrated approach to the patient journey. <i>Journal of Hepatology</i> , 2018, 68, S174-S175.	3.7	1
125	Safety and efficacy of vevatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1331-1340.	2.0	66
126	Sofosbuvir/velpatasvir for 12 weeks in genotype 4 HCV-infected liver transplant recipients. <i>Journal of Hepatology</i> , 2018, 69, 603-607.	3.7	58

#	ARTICLE	IF	CITATIONS
127	Hepatitis C and bleeding disorders in Europe. <i>The Journal of Haemophilia Practice</i> , 2018, 5, 50-65.	0.4	0
128	The impact of antiviral therapy for hepatitis C on the quality of life: a perspective. <i>Liver International</i> , 2017, 37, 7-12.	3.9	24
129	Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study. <i>Infection</i> , 2017, 45, 215-220.	4.7	8
130	Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. <i>Gastroenterology</i> , 2017, 153, 113-122.	1.3	215
131	Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1 without cirrhosis. <i>Journal of Hepatology</i> , 2017, 67, 263-271.	3.7	261
132	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017, 67, 370-398.	3.7	3,803
133	Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, S25.	3.7	13
134	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. <i>Transplantation</i> , 2017, 101, 945-955.	1.0	76
135	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, 956-967.	1.0	44
136	Hepatitis B (HBV) Viral Suppression is Independently Associated with Better Patient-Reported Outcomes (PROS). <i>Gastroenterology</i> , 2017, 152, S1085.	1.3	0
137	Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. <i>Digestive and Liver Disease</i> , 2017, 49, e10-e11.	0.9	0
138	Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. <i>Journal of Hepatology</i> , 2017, 67, 224-236.	3.7	110
139	Hepatitis C in the EU: setting the terms for elimination. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 314-315.	8.1	3
140	Diagnosing liver fibrosis: a narrative review of current literature for dermatologists. <i>British Journal of Dermatology</i> , 2017, 177, 637-644.	1.5	8
141	Virally suppressed patients with chronic HBV infection without cirrhosis have better patient-reported outcomes (PROS). <i>Journal of Hepatology</i> , 2017, 66, S686-S687.	3.7	0
142	Regeneration linked miRNA in acute liver failure can predict clinical recompensation after DAA associated HCV cure: a novel biomarker to inform treatment selection in decompensated HCV cirrhosis?. <i>Journal of Hepatology</i> , 2017, 66, S711.	3.7	0
143	A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, S688-S689.	3.7	26
144	Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study. <i>Gastroenterology</i> , 2017, 152, S1061.	1.3	3

#	ARTICLE	IF	CITATIONS
145	Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 805-813.	8.1	22
146	Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries. <i>Journal of Hepatology</i> , 2017, 67, 1348-1350.	3.7	31
147	Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 900-909.	8.1	217
148	Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 910-919.	8.1	95
149	MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1 infection. <i>Journal of Hepatology</i> , 2017, 66, S90-S91.	3.7	51
150	Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A Global Phase 3 Study. <i>Gastroenterology</i> , 2017, 152, S1085-S1086.	1.3	0
151	Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx067.	0.9	17
152	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. <i>Annals of Hepatology</i> , 2017, 16, 375-381.	1.5	6
153	Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review. <i>BMC Infectious Diseases</i> , 2017, 17, 722.	2.9	32
154	Treatment of Genotype 3 Chronic Hepatitis C Virus Infection. <i>Clinical Medicine Insights Therapeutics</i> , 2017, 9, 1179559X1769433.	0.4	0
155	Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank. <i>International Journal of Epidemiology</i> , 2017, 46, 1391-1391h.	1.9	27
156	Impact of comorbidity on waiting list and post-transplant outcomes in patients undergoing liver retransplantation. <i>World Journal of Hepatology</i> , 2017, 9, 884.	2.0	9
157	Developing a donation after cardiac death risk index for adult and pediatric liver transplantation. <i>World Journal of Transplantation</i> , 2017, 7, 203.	1.6	45
158	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. <i>Annals of Hepatology</i> , 2017, 16, 375-381.	1.5	1
159	PTH-107...Chronic Hepatitis B Management The UK: A National Survey of Current Practice Following Nice Guidance. <i>Gut</i> , 2016, 65, A271.2-A272.	12.1	0
160	Liver Retransplantation in Patients With HIV-1 Infection: An International Multicenter Cohort Study. <i>American Journal of Transplantation</i> , 2016, 16, 679-687.	4.7	11
161	Directly acting antivirals for hepatitis C virus arrive in HIV/hepatitis C virus co-infected patients. <i>Aids</i> , 2016, 30, 975-989.	2.2	5
162	Concentration Monitoring of Plasma Ribavirin. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 50-58.	2.0	4

#	ARTICLE	IF	CITATIONS
163	Does Donation After Cardiac Death Utilization Adversely Affect Hepatocellular Cancer Survival? Transplantation, 2016, 100, 1916-1924.	1.0	31
164	Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology, 2016, 65, 741-747.	3.7	351
165	Antiviral treatment in patients with advanced hepatitis C virus cirrhosis with sofosbuvir and either ledipasvir or daclatasvir, with or without ribavirin: observational cohort study. Lancet, The, 2016, 387, S26.	13.7	1
166	Su1413 Sof/VEL for 12 Weeks Results in High SVR 12 Rates in Subjects With Negative Predictors of Response to Treatment: An Integrated Analysis of Efficacy From the ASTRAL-1, ASTRAL-2 and ASTRAL-3 Studies. Gastroenterology, 2016, 150, S1092.	1.3	0
167	Transcriptomics in Interferon-Î±-Treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression. Neuropsychopharmacology, 2016, 41, 2502-2511.	5.4	48
168	HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy. Hepatology International, 2016, 10, 727-729.	4.2	13
169	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. The Lancet Gastroenterology and Hepatology, 2016, 1, 185-195.	8.1	336
170	Patients who Underwent Percutaneous Coronary Intervention Prior to Liver Transplantation Did Not Experience Bleeding Complications Whilst on Dual Antiplatelet Therapy. Journal of Hepatology, 2016, 64, S541-S542.	3.7	0
171	Antiviral Treatment in Patients with Advanced Hcv Cirrhosis Using Sofosbuvir and Ledipasvir/Daclatasvir with or without Ribavirin - 6 and 12 Month Outcomes Compared to Untreated Patients. Journal of Hepatology, 2016, 64, S185-S186.	3.7	6
172	Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2016, 44, 957-966.	3.7	35
173	Outpatient Liver Transplantation Assessment is an Effective Tool with No Evidence of Delay in Decision Making. Journal of Hepatology, 2016, 64, S541.	3.7	0
174	High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies. Journal of Hepatology, 2016, 64, S759.	3.7	6
175	PWE-037...Reliability of Arfi Shear Velocity Cut-Off for Diagnosis of Cirrhosis in Chronic Hepatitis C: A "Real World" Two Centre Simultaneous Biopsy-Controlled Study in The UK. Gut, 2016, 65, A157.1-A157.	12.1	0
176	812e The Use of Sofosbuvir and Velpatasvir is Associated With High Efficacy and Improvement in Patient-Reported Outcomes in Patients with Genotype 1, 2, 4, 5 and 6 Chronic Hepatitis C: Results from the ASTRAL-1 Clinical Trial. Gastroenterology, 2016, 150, S1267-S1268.	1.3	1
177	Sa1637 High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin Among Patients With Decompensated Cirrhosis Who Underwent Liver Transplant During Participation in the SOLAR-1 and SOLAR-2 Studies. Gastroenterology, 2016, 150, S1083.	1.3	1
178	Pregnancy and liver disease. Journal of Hepatology, 2016, 64, 933-945.	3.7	201
179	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infectious Diseases, The, 2016, 16, 685-697.	9.1	402
180	Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology, 2016, 64, 1224-1231.	3.7	425

#	ARTICLE	IF	CITATIONS
181	Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. <i>Journal of Hepatology</i> , 2016, 65, 33-39.	3.7	103
182	Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. <i>Annals of Hepatology</i> , 2016, 15, 512-23.	1.5	3
183	Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts. <i>Liver Transplantation</i> , 2015, 21, 29-37.	2.4	27
184	Outcomes of pregnancy following liver transplantation: The King's College Hospital experience. <i>Liver Transplantation</i> , 2015, 21, 1153-1159.	2.4	75
185	Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana. <i>Clinical Infectious Diseases</i> , 2015, 61, 883-891.	5.8	53
186	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2599-2607.	27.0	945
187	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2608-2617.	27.0	740
188	Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 608-610.	5.8	25
189	STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2015, 62, 1246-1255.	3.7	19
190	Cutaneous side-effects of antihepatitis C treatment: the U.K. experience. <i>British Journal of Dermatology</i> , 2015, 172, 292-293.	1.5	5
191	Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. <i>Journal of Hepatology</i> , 2015, 62, 533-540.	3.7	161
192	Hepatitis delta virus testing, epidemiology and management: A multicentre cross-sectional study of patients in London. <i>Journal of Clinical Virology</i> , 2015, 66, 33-37.	3.1	39
193	Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK. <i>Clinical Microbiology and Infection</i> , 2015, 21, 1033-1039.	6.0	21
194	Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection. <i>Gastroenterology</i> , 2015, 149, 1462-1470.	1.3	214
195	Faldaprevir for the treatment of genotype-1 hepatitis C virus. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 277-288.	3.0	2
196	Hope for non-responders with hepatitis C virus and cirrhosis. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 363-365.	9.1	2
197	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: Table 1. <i>Cut</i> , 2015, 64, 1824-1833.	12.1	128
198	Hepatitis C treatment and quality of life "You can't always get what you want, but you might get what you need. <i>Journal of Hepatology</i> , 2015, 63, 300-302.	3.7	7

#	ARTICLE	IF	CITATIONS
199	Controlling hepatitis C with simeprevir. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 2-4.	9.1	1
200	Role of liver transplantation in human immunodeficiency virus positive patients. <i>World Journal of Gastroenterology</i> , 2015, 21, 12311.	3.3	15
201	Towards the elimination and eradication of hepatitis B. <i>Journal of Virus Eradication</i> , 2015, 1, 4-12.	0.5	5
202	Clinical Factors That Predict Noncirrhotic Portal Hypertension in HIV-Infected Patients: A Proposed Diagnostic Algorithm. <i>Journal of Infectious Diseases</i> , 2014, 209, 734-738.	4.0	11
203	<scp>CXCL</scp>10 levels identify individuals with rapid fibrosis at 12Âmonths postâ€transplant for hepatitis <scp>C</scp> virus and predict treatment response. <i>Clinical Transplantation</i> , 2014, 28, 569-578.	1.6	8
204	Forgotten, not neglected: viral hepatitis in resourceâ€limited settings, recall for action. <i>Liver International</i> , 2014, 34, 12-15.	3.9	19
205	Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV). <i>Gastroenterology</i> , 2014, 146, S-903.	1.3	0
206	Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study. <i>Journal of Hepatology</i> , 2014, 61, 228-234.	3.7	88
207	Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2014, 146, 744-753.e3.	1.3	42
208	Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: â€œA Flood of Opportunityâ€ American Journal of Transplantation, 2014, 14, 994-1002.	4.7	72
209	ABT-450/râ€Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. <i>New England Journal of Medicine</i> , 2014, 370, 1973-1982.	27.0	834
210	Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2014, 370, 1889-1898.	27.0	1,580
211	Natural history of hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, S58-S68.	3.7	706
212	Recurrent HCV after liver transplantationâ€™ mechanisms, assessment and therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 710-721.	17.8	33
213	Review article: 2014 UK consensus guidelines â€ hepatitis C management and directâ€acting antiâ€viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1363-1375.	3.7	32
214	Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model. <i>Journal of Hepatology</i> , 2014, 60, 1118-1126.	3.7	18
215	Liver abnormalities in the immunosuppressed. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 597-618.	2.4	1
216	Treatment of chronic hepatitis C virus infection after liver transplantation. <i>Digestive and Liver Disease</i> , 2013, 45, S349-S354.	0.9	9

#	ARTICLE	IF	CITATIONS
217	Hepatitis C treatment: interferon free or interferon free?. <i>Lancet, The</i> , 2013, 381, 2063-2065.	13.7	2
218	408 HBsAg AND IP-10 PLASMA LEVELS KINETICS DURING THERAPY WITH PEGYLATED INTERFERON AND CONSEQUENT THERAPY WITH NUCLEOS(T)IDE ANALOGUES. <i>Journal of Hepatology</i> , 2013, 58, S167-S168.	3.7	0
219	Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation. <i>Liver Transplantation</i> , 2013, 19, 383-394.	2.4	29
220	905 ADHERENCE WITH TELAPREVIR BID vs. q8h DOSING IN TREATMENT-NAÏVE HCV-INFECTED PATIENTS: RESULTS FROM THE PHASE III OPTIMIZE STUDY. <i>Journal of Hepatology</i> , 2013, 58, S373.	3.7	3
221	738 SWITCH FROM LONG-TERM DE-NOVO LAMIVUDINE + ADEFOVIR THERAPY TO TENOFOVIR OR/AND ENTECAVIR IMPROVES VIRAL RESPONSE AND RENAL/BONE SAFETY. <i>Journal of Hepatology</i> , 2013, 58, S299.	3.7	1
222	Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 659-671.	3.7	13
223	Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. <i>Liver International</i> , 2013, 33, 137-150.	3.9	43
224	The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. <i>Liver International</i> , 2013, 33, 53-61.	3.9	74
225	The Diversity and Management of Chronic Hepatitis B Virus Infections in the United Kingdom: A Wake-up Call. <i>Clinical Infectious Diseases</i> , 2013, 56, 951-960.	5.8	35
226	Maintaining clinical governance when giving telephone advice. <i>Frontline Gastroenterology</i> , 2013, 4, 270-277.	1.8	0
227	British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. <i>HIV Medicine</i> , 2013, 14, 1-71.	2.2	43
228	The association of pretransplant ferritin level with waiting list and post-transplant survival. Does ferritin actually predict outcome?. <i>Transplant International</i> , 2013, 26, 1070-1079.	1.6	11
229	Patient perception of skin-cancer prevention and risk after liver transplantation. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 851-856.	1.3	15
230	PTH-178...Who Calls the Liver Registrar at King's?. <i>Gut</i> , 2013, 62, A283.3-A284.	12.1	0
231	Tenofovir-based combination therapy for HIV/HBV co-infection. <i>Aids</i> , 2013, 27, 1443-1448.	2.2	23
232	Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naïve Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial. <i>American Journal of Gastroenterology</i> , 2013, 108, S145.	0.4	2
233	Hepatitis E "an unexpected problem at home. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 253-253.	1.5	14
234	New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye: Table 1. <i>Gut</i> , 2012, 61, 1647-1652.	12.1	23

#	ARTICLE	IF	CITATIONS
235	PMO-178â€¦The significance of viral and serological markers in predicting liver disease severity in e-Ag negative hepatitis b virus infection. Gut, 2012, 61, A146.1-A146.	12.1	0
236	PTU-059â€¦Hepatitis C virus infection abrogates the effect of liver transplantation on NK cell activation. Gut, 2012, 61, A208.1-A208.	12.1	0
237	PTU-016â€¦Functional defects in circulating monocytes may contribute to susceptibility to infection in alcoholic hepatitis: Abstract PTU-016a Figure 1. Gut, 2012, 61, A189.2-A190.	12.1	0
238	225 REDUCING RISK FACTORS FOR SKIN CANCER DEVELOPMENT FOLLOWING LIVER TRANSPLANT - THE NEED FOR MORE EFFECTIVE PATIENT EDUCATION AND HEALTH PROMOTION. Journal of Hepatology, 2012, 56, S95.	3.7	0
239	Interruption of mother-to-infant transmission of hepatitis B: time to include selective antiviral prophylaxis?. Lancet, The, 2012, 379, 2019-2021.	13.7	24
240	<scp>UK</scp> consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis <scp>C</scp> infected patients. Alimentary Pharmacology and Therapeutics, 2012, 35, 647-662.	3.7	76
241	1367 NONCIRRHOTIC PORTAL HYPERTENSION (NCPH) IN HIV-INFECTED PATIENTS: A CASE CONTROL STUDY. Journal of Hepatology, 2012, 56, S537.	3.7	0
242	Review of the neurological manifestations of hepatitis E infection. Annals of Hepatology, 2012, 11, 618-622.	1.5	71
243	Development and validation of an efficient in-house real-time reverse transcription polymerase chain reaction assay for the quantitative detection of serum hepatitis delta virus RNA in a diverse South London population. Journal of Virological Methods, 2012, 184, 55-62.	2.1	21
244	The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology, 2012, 55, 749-758.	7.3	108
245	1145 HIGH NUMBERS OF CD56BRIGHT, CD56DIM/NKG2D+ AND LOW NUMBERS OF CD3 CD56 CD16+ NK-CELLS ARE ASSOCIATED WITH LOW HCV-SPECIFIC IL-10 PRODUCTION AND PREDICT TREATMENT-RESPONSE IN CHRONIC HEPATITIS C. Journal of Hepatology, 2011, 54, S452-S453.	3.7	0
246	Massive Gastrointestinal Bleed in a Patient With Primary Sclerosing Cholangitis. Gastroenterology, 2011, 140, e7-e8.	1.3	0
247	Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. New England Journal of Medicine, 2011, 364, 2405-2416.	27.0	2,278
248	Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology, 2011, 54, 1538-1546.	7.3	49
249	549 THE UK EXPERIENCE OF LIVER TRANSPLANTATION IN PATIENTS RECEIVING OPIATE REPLACEMENT THERAPY. Journal of Hepatology, 2011, 54, S224.	3.7	0
250	Increasing burden of liver disease in patients with HIV infection. Lancet, The, 2011, 377, 1198-1209.	13.7	258
251	P47 De-novo antiviral therapy with nucleos(t)ide analogues in 'real-life' patients with chronic hepatitis B infection: comparison of virological responses between lamivudine + adefovir vs entecavir vs tenofovir therapy. Gut, 2011, 60, A22-A23.	12.1	3
252	P67 Switch to other nucleos(t)ide analogues therapy in chronic hepatitis B cohort on long-term de-novo combination therapy with lamivudine plus adefovir: efficacy and safety. Gut, 2011, 60, A31-A31.	12.1	0

#	ARTICLE	IF	CITATIONS
253	P77 A Pharmacist delivered stratified conversion protocol from Hepatitis B Immunoglobulin (HBIG) to tenofovir or entecavir is efficacious, safe and cost-effective for prevention of recurrence of Hepatitis B virus (HBV) in Liver Transplant (LT) recipients. Gut, 2011, 60, A35-A36.	12.1	0
254	The UK experience of liver transplantation in patients receiving opiate replacement therapy. Gut, 2011, 60, A58-A59.	12.1	0
255	P100 Liver transplantation (LT) results in reduced recipient Natural Killer (NK) cell activation with associated down regulation of activating receptors NKp30 and NKp46 but not NKG2D. Gut, 2011, 60, A46-A47.	12.1	0
256	P57 The IL28B gene SNP rs12979860 CC haplotype, predictor of response to treatment in chronic HCV infection, is associated to high numbers of CD56bright NK cells, low numbers of CD3-CD56-CD16+ NK cells and low HCV-specific IL-10 production. Gut, 2011, 60, A26-A27.	12.1	0
257	Cholangiocarcinoma complicating recurrent primary sclerosing cholangitis after liver transplantation. Transplant International, 2011, 24, e93-e96.	1.6	20
258	Liver transplantation in human immunodeficiency virus-positive patients. Liver Transplantation, 2011, 17, 881-890.	2.4	18
259	Final Results of Open-Label Treatment with Eltrombopag During ENABLE 1: A Study of Eltrombopag As An Adjunct for Antiviral Treatment of Hepatitis C Virus Associated with Thrombocytopenia. Blood, 2011, 118, 2232-2232.	1.4	4
260	Patient access. How to wipe out a growing killer. The Health Service Journal, 2011, 121, 20-2.	0.0	0
261	Predictors of graft and patient survival in subjects transplanted for HCV infection. Liver Transplantation, 2010, 16, NA-NA.	2.4	0
262	British HIV Association guidelines for the management of coinfection with HIV and hepatitis B or C virus 2010. HIV Medicine, 2010, 11, 1-30.	2.2	73
263	PTU-060...Primary sclerosing cholangitis post liver transplantation—the impact of inflammatory bowel disease. Gut, 2010, 59, A73.1-A73.	12.1	0
264	Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut, 2010, 59, 1245-1251.	12.1	273
265	Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. New England Journal of Medicine, 2009, 360, 1839-1850.	27.0	1,004
266	Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transplantation, 2008, 14, 861-871.	2.4	126
267	Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach. Gastroenterology, 2008, 134, 405-415.	1.3	215
268	Ribavirin considerations in treatment optimization. Antiviral Therapy, 2008, 13 Suppl 1, 23-30.	1.0	7
269	Ribavirin considerations in treatment optimization. Antiviral Therapy, 2008, 13, 23-30.	1.0	17
270	Chronic Ductopenic Rejection in Patients With Recurrent Hepatitis C Virus Treated With Pegylated Interferon Alfa-2a and Ribavirin. Transplantation, 2007, 84, 180-186.	1.0	53

#	ARTICLE	IF	CITATIONS
271	Do Laparoscopy and Intraoperative Ultrasound Have a Role in the Assessment of Patients With End-Stage Liver Disease and Hepatocellular Carcinoma for Liver Transplantation?. <i>Transplantation Proceedings</i> , 2007, 39, 1474-1476.	0.6	7
272	A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. <i>Tissue Antigens</i> , 2007, 69, 227-235.	1.0	82
273	The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant. <i>Anaesthesia</i> , 2007, 62, 282-285.	3.8	9
274	Pegylated interferon- α induced immune-mediated hepatitis post-liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 827-830.	2.4	64
275	Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. <i>Liver Transplantation</i> , 2006, 12, 1496-1503.	2.4	101
276	Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantation. <i>Gut</i> , 2006, 55, 863-868.	12.1	26
277	Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B: a review of the major clinical studies. <i>Journal of Hepatology</i> , 2003, 39, 116-123.	3.7	8
278	Hepatitis associated with Chinese herbs. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 559-562.	1.6	69
279	Familial primary biliary cirrhosis and autoimmune cholangitis. <i>Digestive and Liver Disease</i> , 2002, 34, 50-52.	0.9	6
280	Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. <i>Hepatology</i> , 2000, 31, 49-53.	7.3	233
281	Genetic susceptibility to primary biliary cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 603-606.	1.6	37
282	Treatment of hepatitis C infection. <i>BMJ: British Medical Journal</i> , 1999, 319, 450-450.	2.3	2
283	Alpha interferon for hepatitis C virus infection in haemophilic patients. <i>Haemophilia</i> , 1995, 1, 54-58.	2.1	36
284	Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to interferon- α . <i>Hepatology</i> , 1992, 15, 1002-1006.	7.3	33